ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Synthetic Biologics Discontinues Study of SYN-010 in IBS-C Patients
October 12, 2020Synthetic Biologics has announced the results of a planned interim futility analysis of the investigator-sponsored Phase 2b clinical study of SYN-010 being conducted by Cedars-Sinai Medical Center (CSMC). -
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 15, 2017Ardelyx reported positive, topline results from the T3MPO-1 trial, the first of two Phase 3 trials evaluating tenapanor for the treatment of patients with irritable bowel syndrome with constipation (IBS-C).
Pharma Sources Insight January 2025
